Analysts expect that Check Cap Ltd (NASDAQ:CHEK) will post earnings per share of ($0.54) for the current fiscal quarter, Zacks reports. Zero analysts have provided estimates for Check Cap’s earnings. Check Cap reported earnings of ($11.28) per share during the same quarter last year, which indicates a positive year-over-year growth rate of 95.2%. The firm is scheduled to issue its next earnings results on Wednesday, April 3rd.
According to Zacks, analysts expect that Check Cap will report full year earnings of ($2.57) per share for the current year. For the next fiscal year, analysts forecast that the firm will report earnings of ($1.40) per share. Zacks’ earnings per share calculations are a mean average based on a survey of sell-side research analysts that that provide coverage for Check Cap.
Check Cap (NASDAQ:CHEK) last announced its quarterly earnings results on Monday, November 5th. The medical research company reported ($0.50) earnings per share for the quarter, topping the consensus estimate of ($0.53) by $0.03.
Separately, HC Wainwright set a $14.00 price target on Check Cap and gave the stock a “buy” rating in a research report on Tuesday, November 6th.
Institutional investors and hedge funds have recently made changes to their positions in the business. Renaissance Technologies LLC acquired a new stake in shares of Check Cap during the 2nd quarter valued at about $524,000. Fosun International Ltd acquired a new stake in shares of Check Cap during the 2nd quarter valued at about $517,000. Finally, Dimensional Fund Advisors LP acquired a new stake in shares of Check Cap during the 3rd quarter valued at about $141,000. 1.55% of the stock is currently owned by institutional investors.
Shares of CHEK opened at $3.22 on Monday. Check Cap has a fifty-two week low of $3.08 and a fifty-two week high of $19.78.
About Check Cap
Check-Cap Ltd., a clinical stage medical diagnostics company, engages in the development of a capsule-based system that utilizes low-dose X-rays for screening of the colon to detect polyps, masses, and colorectal cancers in Israel. Its C-Scan system consists of C-Scan Cap, an X-ray scanning capsule, which is designed to measure, collect, and transmit structural information; C-Scan Track, a biocompatible unit worn on the patient's back for capsule control, tracking, and data recording; and C-Scan View, a personal computer-based software package, which is designed to retrieve and process clinical data from the C-Scan Track, and to reconstruct and produce 3D visualization of the colon's inner surface.
Featured Article: Insider Trading
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Check Cap Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Check Cap and related companies with MarketBeat.com's FREE daily email newsletter.